AstraZeneca has struck a deal with TerSera Therapeutics LLC for the commercial rights to Zoladex (goserelin acetate implant) in the United States and Canada for $150 million. Used to treat prostate cancer, breast cancer and certain benign gynaecological disorders, the drug was first approved in 1989.
AstraZeneca will also receive sales-related income up to $70 million. AstraZeneca will manufacture and supply Zoladex to TerSera.
In 2016, sales for Zoladex were $69 million in the United States and Canada and $816 million globally. The transaction is expected to complete in the first quarter of 2017. AstraZeneca will maintain a significant ongoing interest in Zoladex in the United States and Canada.